Literature DB >> 23769887

Liver disease in cystic fibrosis.

Lisette Leeuwen1, Dominic A Fitzgerald2, Kevin J Gaskin3.   

Abstract

The survival of patients with cystic fibrosis (CF) has progressively increased over recent decades, largely attributable to early diagnosis through newborn screening and advances in nutritional and respiratory care. As the life expectancy of patients with CF has improved, non-respiratory complications such as liver disease have become increasingly recognized. Biochemical derangements of liver enzymes in CF are common and may be attributed to a number of specific hepatobiliary abnormalities. Among them, Cystic Fibrosis-associated Liver Disease (CFLD) is clinically the most significant hepatic complication and is believed to have a significant impact on morbidity and mortality. However, there remains much conjecture about the extent of the adverse prognostic implications that a diagnosis of CFLD has on clinical outcomes. The purpose of this review is to give an overview of the current knowledge regarding liver disease in children with CF. Crown
Copyright © 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cholestasis; Cystic Fibrosis; Cystic Fibrosis-associated Liver Disease; Liver transplantation; Morbidity; Mortality

Mesh:

Year:  2013        PMID: 23769887     DOI: 10.1016/j.prrv.2013.05.001

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  17 in total

1.  Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy.

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Hepatology       Date:  2018-01-26       Impact factor: 17.425

Review 2.  Cystic fibrosis: a clinical view.

Authors:  Carlo Castellani; Baroukh M Assael
Journal:  Cell Mol Life Sci       Date:  2016-10-05       Impact factor: 9.261

3.  Directed differentiation of cholangiocytes from human pluripotent stem cells.

Authors:  Mina Ogawa; Shinichiro Ogawa; Christine E Bear; Saumel Ahmadi; Stephanie Chin; Bin Li; Markus Grompe; Gordon Keller; Binita M Kamath; Anand Ghanekar
Journal:  Nat Biotechnol       Date:  2015-07-13       Impact factor: 54.908

Review 4.  [Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults].

Authors:  S Hohenester; U Beuers
Journal:  Internist (Berl)       Date:  2017-08       Impact factor: 0.743

Review 5.  Ursodeoxycholic acid for cystic fibrosis-related liver disease.

Authors:  Katharine Cheng; Deborah Ashby; Rosalind L Smyth
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11

6.  Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes.

Authors:  Divya Ramnath; Katharine M Irvine; Samuel W Lukowski; Leigh U Horsfall; Zhixuan Loh; Andrew D Clouston; Preya J Patel; Kevin J Fagan; Abishek Iyer; Guy Lampe; Jennifer L Stow; Kate Schroder; David P Fairlie; Joseph E Powell; Elizabeth E Powell; Matthew J Sweet
Journal:  JCI Insight       Date:  2018-07-26

Review 7.  Liver Organoids: Formation Strategies and Biomedical Applications.

Authors:  Xinglong Zhu; Bingqi Zhang; Yuting He; Ji Bao
Journal:  Tissue Eng Regen Med       Date:  2021-06-16       Impact factor: 4.451

Review 8.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-05-13       Impact factor: 5.577

Review 9.  Circulating microRNAs and Bioinformatics Tools to Discover Novel Diagnostic Biomarkers of Pediatric Diseases.

Authors:  Antonella Baldassarre; Cristina Felli; Giorgio Prantera; Andrea Masotti
Journal:  Genes (Basel)       Date:  2017-09-19       Impact factor: 4.096

10.  Opposite Expression of Hepatic and Pulmonary Corticosteroid-Binding Globulin in Cystic Fibrosis Patients.

Authors:  Anastasia Tchoukaev; Jessica Taytard; Nathalie Rousselet; Carine Rebeyrol; Dominique Debray; Sabine Blouquit-Laye; Marie-Pierre Moisan; Aline Foury; Loic Guillot; Harriet Corvol; Olivier Tabary; Philippe Le Rouzic
Journal:  Front Pharmacol       Date:  2018-06-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.